120 related articles for article (PubMed ID: 17204405)
1. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Sun HK; Du X; DeRyke CA; Doern GV; Nicolau DP
Int J Antimicrob Agents; 2007 Feb; 29(2):230-2. PubMed ID: 17204405
[No Abstract] [Full Text] [Related]
2. Identification of a novel resistance mutation in parE that confers high-level resistance to moxifloxacin in Streptococcus pneumoniae.
Zhang G; Tian W; Wang C; Feng J
J Antimicrob Chemother; 2012 Nov; 67(11):2773-4. PubMed ID: 22761332
[No Abstract] [Full Text] [Related]
3. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
6. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Hovde LB; Simonson DA; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
8. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
9. The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Dobay O; Rozgonyi F; Ghidán A; Matuz M; Nagy K; Amyes SG
J Chemother; 2006 Dec; 18(6):624-7. PubMed ID: 17267340
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
12. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
14. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Smith HJ; Noreddin AM; Siemens CG; Schurek KN; Greisman J; Hoban CJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2004 Sep; 48(9):3630-5. PubMed ID: 15328145
[TBL] [Abstract][Full Text] [Related]
15. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
Hart D; Weinstein MP
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
[TBL] [Abstract][Full Text] [Related]
19. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
20. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
De Vecchi E; Nicola L; Ossola F; Drago L
J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
